Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
Rhea-AI Summary
Biofrontera (Nasdaq: BFRI) will report fourth quarter and full year 2025 financial results after U.S. market close on Thursday, March 19, 2026. The company will host a conference call and webcast on March 19, 2026 at 10:00 a.m. ET to discuss results and provide a business update.
Dial-in numbers and a webcast link are provided for investor access.
Positive
- None.
Negative
- None.
News Market Reaction – BFRI
In the Mar 10 session, BFRI gained 0.73%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.7% during that session. Argus tracked a trough of -13.8% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Earnings date announcement | Neutral | -6.9% | Set Q3 2025 earnings release and conference call schedule. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date scheduling news saw a negative move of -6.9%; today’s pre-announcement weakness of -4.07% is directionally consistent.
This announcement sets the date for Biofrontera’s Q4 and full-year 2025 results following a series of material updates. Recent news included record preliminary Q4 2025 revenues of $17.0–$17.5 million and full-year revenues of $41.5–$42.0 million, multiple positive Ameluz® clinical milestones with sNDA plans, and a favorable PTAB decision against a Sun Pharma patent. At the same time, filings highlighted tight liquidity, going-concern warnings, strategic asset sales, and Nasdaq listing compliance challenges, providing important context ahead of the detailed March 19 release.
Key Terms
photodynamic therapy (pdt) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call |
| Date: | Thursday, March 19, 2026 |
| Time: | 10:00 a.m. ET |
| Conference Call: | 1-888-222-5806 (U.S.) 1-412-902-6516 (international) |
| Webcast: | Webcast – Biofrontera Inc. 4Q25 and Full Year 2025 Results Conference Call https://event.choruscall.com/mediaframe/webcast.html?webcastid=XTq1cPRZ |
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera’s commercial opportunities and the commercial success of its products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® and/or RhodoLED® XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
1 https://www.skincancer.org/skin-cancer-information/actinic-keratosis/
